Linagliptin-Metformin Linagliptin-Metformin Stada 2,5 Mg/500 Mg Filmtabletta

Linagliptin, the active ingredient in Linagliptin‑Metformin Stada 2,5 Mg/500 Mg Filmtabletta, is a DPP‑4 inhibitor presented as a 2.5 mg/500 mg film‑coated tablet for oral use. It treats type 2 diabetes mellitus in adults, often in combination with diet and exercise.

GNH USA supplies Linagliptin‑Metformin Stada 2,5 Mg/500 Mg Filmtabletta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin/Metformin is indicated for the management of type 2 diabetes mellitus, targeting hyperglycaemia through complementary mechanisms.

- Type 2 diabetes mellitus: improves glycaemic control as part of combination therapy. - Inadequate control on metformin alone: adds DPP‑4 inhibition to further lower HbA1c. - Fixed‑dose combination therapy: simplifies regimen and enhances patient adherence.

Common Side Effects: - Nausea: mild to moderate gastrointestinal discomfort. - Diarrhoea: loose stools, usually transient. - Headache: mild tension‑type pain. - Nasopharyngitis: upper respiratory symptoms. - Dizziness: occasional light‑headedness. - Abdominal pain: mild cramping.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe hypersensitivity: rash, angioedema, or anaphylaxis. - Hepatic failure: signs of liver dysfunction. - Hypoglycaemia: when combined with insulin or sulfonylureas. - Renal impairment: worsening kidney function may occur.

Before initiating therapy, evaluate patient-specific risk factors and monitor regularly. - Renal function assessment: check eGFR prior to start and periodically thereafter. - Hepatic impairment: use with caution in patients with liver disease. - Risk of lactic acidosis: avoid in severe renal or hepatic dysfunction. - Pregnancy and lactation: safety not established; consider alternative agents. - Drug interactions: review concomitant medicines that affect renal clearance or increase hypoglycaemia risk. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Linagliptin/Metformin may interact with several medicines; monitor and adjust therapy as needed.

Major Interactions (Avoid): - Severe renal impairment (eGFR <30 mL/min/1.73 m²): contraindicated. - Co‑administration with other DPP‑4 inhibitors: duplicate therapy risk. - Use with high‑dose metformin in hepatic failure: heightened lactic acidosis risk.

Moderate Interactions (Monitor Closely): - Sulfonylureas or insulin: increased hypoglycaemia potential. - Iodinated contrast media: temporary renal function decline; monitor renal parameters.